FDA Accepts BLA for Proposed Biosimilar to Bevacizumab, MYL-1402O

The biologics license application was supported by findings from a global, randomized, controlled phase III clinical trial, evaluating the efficacy, safety, and immunogenicity of MYL-1402O versus bevacizumab.

Identifying Patient Likelihood to Develop Cachexia Within Different Cancer Types

This study examined both cachexia-inducing factors and patients with various cancers to better understand the disparity between cancer types and developing cachexia.

New Genetic Structural Variants Identified in Childhood Leukemias

Previously unrecognized genetic structural variants in childhood leukemias could be used to evaluate the presence of minimal residual disease during chemotherapy and help to determine response to various therapies.